Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.51 |
| ▸ | STAMBP | O95630 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539018 | 0.85 | FYN (0.47) | CD274CAMK2D | |
| SCHEMBL6538498 | 0.83 | HPGD (0.44) | ADORA2AADORA1CD274HPGD | |
| SCHEMBL6538755 | 0.83 | HSD17B10 (0.46) | HPGDKMT2ACAMK2D | |
| SCHEMBL6133506 | 0.82 | KDM5B (0.49) | ADORA2AADORA1CD274HPGDHPGDS | |
| SCHEMBL6538462 | 0.81 | HPGDS (0.52) | PSMD14HPGDSKMT2A | |
| SCHEMBL6539298 | 0.80 | BAZ2B (0.49) | PSMD14STAMBP | |
| SCHEMBL6539037 | 0.79 | NTRK1 (0.43) | KMT2A | |
| SCHEMBL6539054 | 0.78 | LMNA (0.49) | ADORA2AADORA1PSMD14STAMBPLMNA | |
| SCHEMBL6539043 | 0.78 | TP53 (0.49) | HPGDLMNA | |
| SCHEMBL6538809 | 0.77 | MEN1 (0.44) | HPGDPSMD14LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | ADORA1, ADORA2A, P2RX5 | ADORA2A 2/4885ADORA1 1/4885CD274 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.